Impact Biomedical (IBO) Net Cash Flow (2022 - 2026)

Impact Biomedical (IBO) has 5 years of Net Cash Flow data on file, last reported at $17000.0 in Q1 2026.

• Quarterly Net Cash Flow rose 102.5% year-over-year to $17000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 million (down 190.42% YoY) and the FY2025 annual result came in at -$2.0 million, down 199.9% from the prior year.
• Net Cash Flow slipped to $17000.0 in Q1 2026, from $100000.0 in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $2.7 million in Q3 2024 to a low of -$694000.0 in Q2 2025.
• A 5-year average of -$200.0 and a median of -$1000.0 in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2024 — Net Cash Flow soared 1246.46% — and 2025, when it sank 69300.0%.
• Tracing IBO's Net Cash Flow over 5 years: stood at -$99000.0 in 2022, then tumbled by 102.02% to -$200000.0 in 2023, then tumbled by 234.5% to -$669000.0 in 2024, then jumped by 114.95% to $100000.0 in 2025, then slumped by 83.0% to $17000.0 in 2026.
• The last three Net Cash Flow figures came in at $17000.0 (Q1 2026), $100000.0 (Q4 2025), and -$612000.0 (Q3 2025), per Business Quant data.